mRNA-1982

Phase 2RNA therapy

Moderna

mRNA-1982 is one of 4 biologic programs targeting Lyme disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lyme DiseaseActive, not recruiting

Lyme DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Lyme Disease

#DrugCompanyPhaseTrials

Achromycin V

WWyeth-Lederle Vaccines

VLA15

3 3

mRNA-1982

Moderna

Phase 2

2 4

Ceftriaxone Treatment

NNantes University Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Lyme Disease

NCT07561294

Clinical

Trials by Indication[1]

Lyme disease2 trials

A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)

Active, not recruiting· Moderna logo

Moderna·Phase 2·NCT07561294·366 enrolled

A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age

Completed· Moderna logo

Moderna·Preclinical·NCT05975099·807 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mRNA-1982. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1982 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1982. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

mRNA-1982

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Lyme disease2 trials

References

Drug Info

Quick Facts

Related News